According to Reuters, Lilly could offer the lowest dose of its popular weight loss drug Zepbound at $149 a month, and Novo’s ...

The Trump administration is reportedly finalizing a deal with Eli Lilly and Novo Nordisk that would lower prices on Wegovy, ...

Important state and national stories, market and business news, sports and entertainment, delivered in quick-hit fashion ...

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year forecasts on Wednesday as sales growth of its ...

The Trump administration is negotiating an agreement with pharmaceutical companies Novo Nordisk and Eli Lilly to offer some ...

U.S. President Donald Trump on Thursday is expected to announce a deal with officials from Eli Lilly and Novo Nordisk cutting the price of weight loss drugs in some cases to $150 a month, CBS reported ...

Pfizer and Novo Nordisk seem to want Metsera bad. Analysts are wondering, though: is the obesity biotech really worth this much effort?

In this week’s edition of InnovationRx, we look at the battle for Metsera, the departure of FDA’s top drug regulator, Kimberly-Clark’s $40 billion Kenvue deal, and more.

Novo Nordisk lowered its forecasts due to slowing sales of its obesity drugs amid competition from Eli Lilly and generic ...

The Trump administration is nearing deals with drugmakers Eli Lilly and Novo Nordisk to offer some of their obesity drugs to ...

The stock of Eli Lilly has a consensus Strong Buy rating among 22 Wall Street analysts. That rating is based on 18 Buy and ...

Discover how Novo Nordisk's pipeline is being restructured to refocus its efforts on high-growth areas like diabetes and ...